胃体炎 中国就医指南

Corpus gastritis is a chronic inflammatory condition localized predominantly to the gastric corpus—the main central body of the stomach—characterized by lymphocytic and plasma cell infiltration of the gastric mucosa, often with glandular atrophy and reduced acid secretion (hypochlorhydria or achlorhydria). Unlike antral-predominant gastritis, which is commonly associated with Helicobacter pylori infection and preserved or elevated acid output, corpus gastritis reflects autoimmune-mediated damage to parietal cells and intrinsic factor-producing chief cells. The pathogenesis centers on loss of immune tolerance: autoantibodies target the H+/K+ ATPase proton pump and intrinsic factor, triggering complement activation, T-cell–mediated cytotoxicity, and progressive mucosal atrophy. This leads to impaired gastric acid production, diminished pepsinogen I secretion, and eventual vitamin B12 malabsorption due to intrinsic factor deficiency—placing patients at high risk for pernicious anemia, iron deficiency, and gastric neuroendocrine tumors (type 1 gastric carcinoids). Epidemiologically, corpus gastritis affects approximately 0.5–2% of the general population, with prevalence rising sharply with age—reaching 5–10% in adults over 60 years. It is significantly more common in women (female-to-male ratio ~3:1) and strongly associated with other autoimmune disorders, including Hashimoto’s thyroiditis, type 1 diabetes mellitus, vitiligo, and Addison’s disease. Key risk factors include genetic predisposition (HLA-DRB1*03:01 and *04:01 alleles), female sex, advancing age, and coexisting autoimmune conditions. While many patients remain asymptomatic for years, symptomatic individuals may experience nonspecific upper gastrointestinal complaints such as early satiety, postprandial fullness, mild epigastric discomfort, fatigue, glossitis, or neurological manifestations (e.g., paresthesia, gait instability) secondary to B12 deficiency. Importantly, dyspepsia is often absent or mild despite significant histologic damage—making endoscopic and serologic evaluation essential for diagnosis. Quality of life impact is multifaceted: chronic fatigue and cognitive fog from micronutrient deficiencies impair work performance and daily functioning; dietary restrictions (e.g., avoidance of raw seafood due to bacterial overgrowth risk in achlorhydria) reduce social engagement; and long-term surveillance endoscopy (every 3–5 years) induces anxiety and logistical burden. Untreated, corpus gastritis carries a 1–3% lifetime risk of gastric adenocarcinoma, particularly in the context of extensive atrophy, intestinal metaplasia, and persistent inflammation—underscoring the importance of timely diagnosis, nutritional repletion (parenteral or high-dose oral B12), and structured endoscopic monitoring.

# 胃体炎治疗方案与费用明细（消化内科）

一、非手术/保守治疗方案

适用人群：轻中度慢性胃体炎、幽门螺杆菌阴性或初治患者、无出血/萎缩/肠化者。

• •基础药物治疗（4–8周）：PPI（如艾司奥美拉唑）+胃黏膜保护剂（瑞巴派特）+维生素B12（伴萎缩者）

• •HP根除四联疗法（阳性者）：含铋剂标准方案（阿莫西林+克拉霉素+PPI+枸橼酸铋钾）

• •理疗辅助：低频脉冲胃电刺激（需门诊评估后启用）

二、内镜下介入治疗（非手术核心干预）

适用人群：重度萎缩伴中重度肠化/低级别上皮内瘤变（LGIN）、反复出血性胃体炎。

• •高清放大内镜+NBI评估+靶向活检：术前检查费（血常规、凝血、心电图、胸片）共520元
• •内镜下氩离子凝固术（APC）或射频消融（RFA）（限局灶病变）

三、特殊复杂情况方案

耐药HP感染、重度萎缩伴高级别瘤变（HGIN）或早期癌变：转诊至消化内镜中心行ESD切除

• •全套费用（含术前增强CT、超声内镜EUS评估、ESD手术、术后病理及随访）：28,500–42,000元

方案快速选择指南

• •预算≤2,000元/年：首选PPI+黏膜保护剂保守治疗；
• •确诊HP阳性+中度炎症：根除治疗（推荐1,800元档四联方案）；
• •病理提示LGIN/HGIN：立即启动内镜介入或ESD评估（勿延误）。